Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJFA35)

• DTT Name: Interleukin-15 (IL15)
• Synonyms: IL-15
• Gene Name: IL15
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Cytokine: interleukin
• UniProt ID: IL15_HUMAN
• TTD ID: T32240
• Sequence:
  MRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKI
  EDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANN
  SLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
• Function: Stimulation by IL15 requires interaction of IL15 with components of the IL2 receptor, including IL2RB and probably IL2RG but not IL2RA. In neutrophils, stimulates phagocytosis probably by signaling through the IL15 receptor, composed of the subunits IL15RA, IL2RB and IL2RG, which results in kinase SYK activation. Cytokine that stimulates the proliferation of T-lymphocytes.
• KEGG Pathway:
  Cytokine-cytokine receptor interaction (hsa04060)
  Jak-STAT signaling pathway (hsa04630)
  TNF signaling pathway (hsa04668)
  Intestinal immune network for IgA production (hsa04672)
  HTLV-I infection (hsa05166)
  Herpes simplex infection (hsa05168)
  Rheumatoid arthritis (hsa05323)
• Reactome Pathway: Interleukin-15 signaling (R-HSA-8983432)

Molecular Interaction Atlas (MIA) of This DTT

5 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG-714	DM1T3KQ	Coeliac disease	DA95	Phase 2	[1]
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[2]
SAR445877	DM91KZL	Aggressive cancer	2A00-2F9Z	Phase 2	[3]
N-803	DM4ZN8M	Human immunodeficiency virus infection	1C62	Phase 1	[4]
PF-07209960	DM1W90B	Aggressive cancer	2A00-2F9Z	Phase 1	[5]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Rheumatoid arthritis	FA20	Synovial tissue	2.95E-01	0.2	0.49

References

• [1] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [2] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [3] Clinical pipeline report, company report or official report of Sanofi
• [4] The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.
• [5] ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.